Mersana Therapeutics (MRSN) Stock Forecast, Price Target & Predictions
MRSN Stock Forecast
Mersana Therapeutics stock forecast is as follows: an average price target of $3.00 (represents a 63.04% upside from MRSN’s last price of $1.84) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
MRSN Price Target
The average price target for Mersana Therapeutics (MRSN) is $3.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 63.04% upside from MRSN's last price of $1.84.
MRSN Analyst Ratings
According to 5 Wall Street analysts, Mersana Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MRSN stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Mersana Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | Collen Kusy | Robert W. Baird | $3.00 | $1.35 | 122.22% | 63.04% |
The latest Mersana Therapeutics stock forecast, released on Aug 14, 2024 by Collen Kusy from Robert W. Baird, set a price target of $3.00, which represents a 122.22% increase from the stock price at the time of the forecast ($1.35), and a 63.04% increase from MRSN last price ($1.84).
Mersana Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $3.00 | $3.00 |
| Last Closing Price | $1.84 | $1.84 | $1.84 |
| Upside/Downside | -100.00% | 63.04% | 63.04% |
In the current month, the average price target of Mersana Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mersana Therapeutics's last price of $1.84. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 29, 2024 | Guggenheim | Underperform | Underperform | Hold |
| Feb 29, 2024 | Wedbush | Buy | Buy | Hold |
| Feb 29, 2024 | Wedbush | - | Outperform | Upgrade |
| Feb 28, 2024 | BTIG | - | Buy | Upgrade |
| Dec 04, 2023 | Citigroup | - | Buy | Upgrade |
| Jul 27, 2023 | Scotiabank | - | Sector Outperform | Initialise |
| Jul 27, 2023 | Piper Sandler | - | Overweight | Initialise |
| Jun 15, 2023 | Guggenheim | - | Buy | Initialise |
| Feb 18, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Mersana Therapeutics's last stock rating was published by Guggenheim on Feb 29, 2024. The company gave MRSN a "Underperform" rating, the same as its previous rate.
Mersana Therapeutics Financial Forecast
Mersana Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $10.70M | - | $10.65M | $7.80M | $14.69M | $5.57M | $4.28M | $2.04M | $11.00K | $11.00K | $11.00K | $11.00K | $11.00K | $11.00K | $796.00K | $11.00K | $42.00K | $844.00K |
| Avg Forecast | $1.59M | $1.65M | $1.71M | $1.78M | $5.08M | $5.08M | $5.08M | $5.08M | $6.27M | $7.53M | $8.72M | $8.50M | $14.74M | $9.60M | $12.93M | $14.00M | $15.28M | $56.78M | $2.20M | $17.24M | $5.33K | $120.50K | $170.00K | $312.80K | $202.20K | $439.20K | $306.00K | $390.67K | $583.33K | $350.00K |
| High Forecast | $1.59M | $1.65M | $1.71M | $1.78M | $5.08M | $5.08M | $5.08M | $5.08M | $6.27M | $10.31M | $8.72M | $8.50M | $29.54M | $9.75M | $12.93M | $14.00M | $15.28M | $56.78M | $2.20M | $17.24M | $5.33K | $120.50K | $170.00K | $312.80K | $202.20K | $439.20K | $306.00K | $390.67K | $583.33K | $350.00K |
| Low Forecast | $1.59M | $1.65M | $1.71M | $1.78M | $5.08M | $5.08M | $5.08M | $5.08M | $6.27M | $5.82M | $8.72M | $8.50M | $7.12M | $9.45M | $12.93M | $14.00M | $15.28M | $56.78M | $2.20M | $17.24M | $5.33K | $120.50K | $170.00K | $312.80K | $202.20K | $439.20K | $306.00K | $390.67K | $583.33K | $350.00K |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | - | 0.82% | 0.56% | 0.96% | 0.10% | 1.95% | 0.12% | 2.06% | 0.09% | 0.06% | 0.04% | 0.05% | 0.03% | 2.60% | 0.03% | 0.07% | 2.41% |
Mersana Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $8.50M, with a low forecast of $8.50M, and a high forecast of $8.50M. MRSN's average Quarter revenue forecast represents a -20.54% decrease compared to the company's last Quarter revenue of $10.70M (Dec 23).
Mersana Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-19.00M | - | $-54.31M | $-54.86M | $-45.83M | $-59.64M | $-51.23M | $-46.33M | $-47.79M | $-45.16M | $-40.61M | $-34.37M | $-28.49M | $-22.14M | $-19.45M | $-16.59M | $-15.88M | $-16.38M |
| Avg Forecast | $-1.49M | $-1.54M | $-1.60M | $-1.66M | $-4.73M | $-4.73M | $-4.73M | $-4.73M | $-5.85M | $-7.02M | $-8.13M | $-34.46M | $-13.75M | $-8.96M | $-12.06M | $-36.85M | $-44.02M | $-52.97M | $-2.05M | $-39.41M | $-4.97K | $-112.40K | $-158.58K | $-24.68M | $-188.62K | $-409.69K | $-285.44K | $-17.49M | $-544.14K | $-326.49K |
| High Forecast | $-1.49M | $-1.54M | $-1.60M | $-1.66M | $-4.73M | $-4.73M | $-4.73M | $-4.73M | $-5.85M | $-5.43M | $-8.13M | $-27.56M | $-6.64M | $-8.82M | $-12.06M | $-29.48M | $-35.21M | $-52.97M | $-2.05M | $-31.53M | $-4.97K | $-112.40K | $-158.58K | $-19.74M | $-188.62K | $-409.69K | $-285.44K | $-13.99M | $-544.14K | $-326.49K |
| Low Forecast | $-1.49M | $-1.54M | $-1.60M | $-1.66M | $-4.73M | $-4.73M | $-4.73M | $-4.73M | $-5.85M | $-9.62M | $-8.13M | $-41.35M | $-27.55M | $-9.10M | $-12.06M | $-44.22M | $-52.82M | $-52.97M | $-2.05M | $-47.30M | $-4.97K | $-112.40K | $-158.58K | $-29.61M | $-188.62K | $-409.69K | $-285.44K | $-20.98M | $-544.14K | $-326.49K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.38% | - | 4.50% | 1.49% | 1.04% | 1.13% | 24.94% | 1.18% | 9608.16% | 401.77% | 256.10% | 1.39% | 151.05% | 54.04% | 68.15% | 0.95% | 29.18% | 50.16% |
undefined analysts predict MRSN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Mersana Therapeutics's previous annual EBITDA (undefined) of $NaN.
Mersana Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-18.56M | - | $-54.31M | $-57.15M | $-45.89M | $-60.69M | $-52.98M | $-47.98M | $-49.96M | $-45.47M | $-40.91M | $-34.69M | $-28.84M | $-22.49M | $-19.79M | $-16.93M | $-16.25M | $-16.79M |
| Avg Forecast | $-17.40M | $-17.04M | $-17.33M | $-20.12M | $-23.07M | $-25.09M | $-25.09M | $-25.09M | $-20.60M | $-20.85M | $-20.25M | $-35.15M | $-19.45M | $-43.45M | $-52.99M | $-37.59M | $-45.12M | $484.61K | $-61.84M | $-40.20M | $-79.79M | $-69.01M | $-59.09M | $-24.91M | $-38.68M | $-37.03M | $-35.42M | $-17.84M | $-46.34M | $-45.33M |
| High Forecast | $-17.40M | $-17.04M | $-17.33M | $-20.12M | $-23.07M | $-25.09M | $-25.09M | $-25.09M | $-20.60M | $-17.37M | $-20.25M | $-28.12M | $-13.61M | $-43.45M | $-52.99M | $-30.07M | $-36.09M | $484.61K | $-61.84M | $-32.16M | $-79.79M | $-69.01M | $-59.09M | $-19.93M | $-38.68M | $-37.03M | $-35.42M | $-14.27M | $-46.34M | $-45.33M |
| Low Forecast | $-17.40M | $-17.04M | $-17.33M | $-20.12M | $-23.07M | $-25.09M | $-25.09M | $-25.09M | $-20.60M | $-26.64M | $-20.25M | $-42.18M | $-25.28M | $-43.45M | $-52.99M | $-45.11M | $-54.14M | $484.61K | $-61.84M | $-48.24M | $-79.79M | $-69.01M | $-59.09M | $-29.89M | $-38.68M | $-37.03M | $-35.42M | $-21.41M | $-46.34M | $-45.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | - | 1.02% | 1.52% | 1.02% | -125.24% | 0.86% | 1.19% | 0.63% | 0.66% | 0.69% | 1.39% | 0.75% | 0.61% | 0.56% | 0.95% | 0.35% | 0.37% |
Mersana Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MRSN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Mersana Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $10.13M | - | $18.19M | $18.33M | $14.80M | $14.57M | $14.80M | $12.78M | $10.67M | $10.12M | $8.88M | $7.21M | $5.91M | $5.88M | $5.17M | $4.94M | $4.21M | $4.44M |
| Avg Forecast | $283.14M | $293.64M | $304.52M | $315.81M | $901.77M | $901.77M | $901.77M | $901.77M | $1.11B | $1.34B | $1.55B | $1.51B | $2.62B | $1.71B | $2.30B | $10.17M | $9.83M | $10.09B | $391.27M | $10.87M | $947.61K | $21.41M | $30.21M | $55.58M | $35.93M | $78.04M | $54.37M | $69.42M | $103.65M | $62.19M |
| High Forecast | $283.14M | $293.64M | $304.52M | $315.81M | $901.77M | $901.77M | $901.77M | $901.77M | $1.11B | $1.83B | $1.55B | $1.51B | $5.25B | $1.73B | $2.30B | $12.20M | $11.80M | $10.09B | $391.27M | $13.05M | $947.61K | $21.41M | $30.21M | $55.58M | $35.93M | $78.04M | $54.37M | $69.42M | $103.65M | $62.19M |
| Low Forecast | $283.14M | $293.64M | $304.52M | $315.81M | $901.77M | $901.77M | $901.77M | $901.77M | $1.11B | $1.03B | $1.55B | $1.51B | $1.26B | $1.68B | $2.30B | $8.13M | $7.86M | $10.09B | $391.27M | $8.70M | $947.61K | $21.41M | $30.21M | $55.58M | $35.93M | $78.04M | $54.37M | $69.42M | $103.65M | $62.19M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | - | 0.01% | 1.80% | 1.51% | 0.00% | 0.04% | 1.18% | 11.26% | 0.47% | 0.29% | 0.13% | 0.16% | 0.08% | 0.10% | 0.07% | 0.04% | 0.07% |
Mersana Therapeutics's average Quarter SG&A projection for Mar 24 is $1.51B, based on 3 Wall Street analysts, with a range of $1.51B to $1.51B. The forecast indicates a 14808.15% rise compared to MRSN last annual SG&A of $10.13M (Dec 23).
Mersana Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.13 | - | $-0.47 | $-0.53 | $-0.45 | $-0.62 | $-0.55 | $-0.60 | $-0.69 | $-0.63 | $-0.59 | $-0.50 | $-0.42 | $-0.33 | $-0.33 | $-0.35 | $-0.34 | $-0.35 |
| Avg Forecast | $-0.14 | $-0.14 | $-0.14 | $-0.17 | $-0.19 | $-0.21 | $-0.21 | $-0.21 | $-0.17 | $-0.17 | $-0.17 | $-0.18 | $-0.16 | $-0.36 | $-0.44 | $-0.43 | $-0.49 | - | $-0.51 | $-0.31 | $-0.66 | $-0.57 | $-0.49 | $-0.39 | $-0.32 | $-0.30 | $-0.29 | $-0.37 | $-0.38 | $-0.37 |
| High Forecast | $-0.14 | $-0.14 | $-0.14 | $-0.17 | $-0.19 | $-0.21 | $-0.21 | $-0.21 | $-0.17 | $-0.14 | $-0.17 | $-0.18 | $-0.11 | $-0.36 | $-0.44 | $-0.43 | $-0.49 | - | $-0.51 | $-0.31 | $-0.66 | $-0.57 | $-0.49 | $-0.39 | $-0.32 | $-0.30 | $-0.29 | $-0.37 | $-0.38 | $-0.37 |
| Low Forecast | $-0.14 | $-0.14 | $-0.14 | $-0.17 | $-0.19 | $-0.21 | $-0.21 | $-0.21 | $-0.17 | $-0.22 | $-0.17 | $-0.18 | $-0.21 | $-0.36 | $-0.44 | $-0.43 | $-0.49 | - | $-0.51 | $-0.31 | $-0.66 | $-0.57 | $-0.49 | $-0.39 | $-0.32 | $-0.30 | $-0.29 | $-0.37 | $-0.38 | $-0.37 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | - | 1.08% | 1.24% | 0.91% | -155.35% | 1.08% | 1.94% | 1.05% | 1.11% | 1.21% | 1.27% | 1.32% | 1.08% | 1.13% | 0.95% | 0.89% | 0.94% |
According to undefined Wall Street analysts, Mersana Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MRSN previous annual EPS of $NaN (undefined).
Mersana Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| RLAY | Relay Therapeutics | $5.85 | $19.40 | 231.62% | Buy |
| PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.95 | $7.00 | 137.29% | Buy |
| RCUS | Arcus Biosciences | $15.56 | $33.00 | 112.08% | Buy |
| REPL | Replimune Group | $12.02 | $24.20 | 101.33% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
| VRDN | Viridian Therapeutics | $22.84 | $37.83 | 65.63% | Buy |
| MRSN | Mersana Therapeutics | $1.84 | $3.00 | 63.04% | Buy |
| MRUS | Merus | $51.23 | $77.13 | 50.56% | Buy |
| KURA | Kura Oncology | $17.81 | $26.00 | 45.99% | Buy |
| PTGX | Protagonist Therapeutics | $46.76 | $50.00 | 6.93% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
| HOOK | HOOKIPA Pharma | $3.76 | $3.00 | -20.21% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
MRSN Forecast FAQ
Is Mersana Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Mersana Therapeutics (MRSN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of MRSN's total ratings.
What is MRSN's price target?
Mersana Therapeutics (MRSN) average price target is $3 with a range of $3 to $3, implying a 63.04% from its last price of $1.84. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Mersana Therapeutics stock go up soon?
According to Wall Street analysts' prediction for MRSN stock, the company can go up by 63.04% (from the last price of $1.84 to the average price target of $3), up by 63.04% based on the highest stock price target, and up by 63.04% based on the lowest stock price target.
Can Mersana Therapeutics stock reach $3?
MRSN's average twelve months analyst stock price target of $3 does not support the claim that Mersana Therapeutics can reach $3 in the near future.
What are Mersana Therapeutics's analysts' financial forecasts?
Mersana Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $20.3M (high $20.3M, low $20.3M), average EBITDA is $-18.936M (high $-18.936M, low $-18.936M), average net income is $-98.355M (high $-98.355M, low $-98.355M), average SG&A $3.61B (high $3.61B, low $3.61B), and average EPS is $-0.81 (high $-0.81, low $-0.81). MRSN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $6.74M (high $6.74M, low $6.74M), average EBITDA is $-6.285M (high $-6.285M, low $-6.285M), average net income is $-71.884M (high $-71.884M, low $-71.884M), average SG&A $1.2B (high $1.2B, low $1.2B), and average EPS is $-0.592 (high $-0.592, low $-0.592).
Did the MRSN's actual financial results beat the analysts' financial forecasts?
Based on Mersana Therapeutics's last annual report (Dec 2023), the company's revenue was $36.86M, which missed the average analysts forecast of $51.27M by -28.12%. Apple's EBITDA was $-172M, beating the average prediction of $-71.619M by 139.70%. The company's net income was $-172M, beating the average estimation of $-153M by 11.85%. Apple's SG&A was $59.54M, missing the average forecast of $6.63B by -99.10%. Lastly, the company's EPS was $-1.48, beating the average prediction of $-1.382 by 7.06%. In terms of the last quarterly report (Dec 2023), Mersana Therapeutics's revenue was $10.7M, missing the average analysts' forecast of $14.74M by -27.40%. The company's EBITDA was $-18.998M, beating the average prediction of $-13.75M by 38.16%. Mersana Therapeutics's net income was $-18.561M, missing the average estimation of $-19.449M by -4.56%. The company's SG&A was $10.13M, missing the average forecast of $2.62B by -99.61%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-0.16 by -18.84%